AU2014338864C1 - Oncolytic adenoviruses armed with heterologous genes - Google Patents

Oncolytic adenoviruses armed with heterologous genes Download PDF

Info

Publication number
AU2014338864C1
AU2014338864C1 AU2014338864A AU2014338864A AU2014338864C1 AU 2014338864 C1 AU2014338864 C1 AU 2014338864C1 AU 2014338864 A AU2014338864 A AU 2014338864A AU 2014338864 A AU2014338864 A AU 2014338864A AU 2014338864 C1 AU2014338864 C1 AU 2014338864C1
Authority
AU
Australia
Prior art keywords
seq
sequence
virus
antibody
transgene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014338864A
Other languages
English (en)
Other versions
AU2014338864B2 (en
AU2014338864A8 (en
AU2014338864A1 (en
Inventor
Alice Claire Noel BROWN
Brian Robert Champion
Kerry David Fisher
Tamara NICOLSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akamis Bio Ltd
Original Assignee
Akamis Bio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201318885A external-priority patent/GB201318885D0/en
Priority claimed from GBGB1318880.0A external-priority patent/GB201318880D0/en
Priority claimed from GBGB1322851.5A external-priority patent/GB201322851D0/en
Priority claimed from GB201401159A external-priority patent/GB201401159D0/en
Priority claimed from GB201406470A external-priority patent/GB201406470D0/en
Application filed by Akamis Bio Ltd filed Critical Akamis Bio Ltd
Publication of AU2014338864A1 publication Critical patent/AU2014338864A1/en
Publication of AU2014338864A8 publication Critical patent/AU2014338864A8/en
Publication of AU2014338864B2 publication Critical patent/AU2014338864B2/en
Publication of AU2014338864C1 publication Critical patent/AU2014338864C1/en
Application granted granted Critical
Assigned to Akamis Bio Limited reassignment Akamis Bio Limited Request to Amend Deed and Register Assignors: PSIOXUS THERAPEUTICS LIMITED
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2014338864A 2013-10-25 2014-10-24 Oncolytic adenoviruses armed with heterologous genes Active AU2014338864C1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
GB1322851.5 2013-02-23
GB201318885A GB201318885D0 (en) 2013-10-25 2013-10-25 Adenovirus
GB1318880.0 2013-10-25
GB1318885.9 2013-10-25
GBGB1318880.0A GB201318880D0 (en) 2013-10-25 2013-10-25 Adenovirus
GBGB1322851.5A GB201322851D0 (en) 2013-12-23 2013-12-23 Method
GB1401159.7 2014-01-23
GB201401159A GB201401159D0 (en) 2014-01-23 2014-01-23 Adenovirus
GB1406470.3 2014-04-10
GB201406470A GB201406470D0 (en) 2014-04-10 2014-04-10 Virus
PCT/EP2014/072919 WO2015059303A1 (en) 2013-10-25 2014-10-24 Oncolytic adenoviruses armed with heterologous genes

Publications (4)

Publication Number Publication Date
AU2014338864A1 AU2014338864A1 (en) 2016-05-05
AU2014338864A8 AU2014338864A8 (en) 2018-08-23
AU2014338864B2 AU2014338864B2 (en) 2019-11-21
AU2014338864C1 true AU2014338864C1 (en) 2020-07-16

Family

ID=51900851

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014338864A Active AU2014338864C1 (en) 2013-10-25 2014-10-24 Oncolytic adenoviruses armed with heterologous genes

Country Status (31)

Country Link
US (4) US9987314B2 (enExample)
EP (3) EP3372236A1 (enExample)
KR (1) KR102272932B1 (enExample)
CN (2) CN108064159B (enExample)
AU (1) AU2014338864C1 (enExample)
CA (2) CA2927968C (enExample)
CL (1) CL2016000959A1 (enExample)
CY (1) CY1119955T1 (enExample)
DK (1) DK3021859T3 (enExample)
EA (1) EA036414B1 (enExample)
ES (1) ES2661132T3 (enExample)
HR (1) HRP20180317T1 (enExample)
HU (1) HUE035875T2 (enExample)
IL (2) IL244944B (enExample)
LT (1) LT3021859T (enExample)
MX (1) MX373835B (enExample)
MY (1) MY175614A (enExample)
NO (1) NO3021859T3 (enExample)
NZ (1) NZ718931A (enExample)
PE (1) PE20160951A1 (enExample)
PH (1) PH12016500759B1 (enExample)
PL (1) PL3021859T3 (enExample)
PT (1) PT3021859T (enExample)
RS (1) RS57043B1 (enExample)
SA (1) SA516371011B1 (enExample)
SG (2) SG10201804030WA (enExample)
SI (1) SI3021859T1 (enExample)
SM (1) SMT201800130T1 (enExample)
TR (1) TR201802728T4 (enExample)
WO (1) WO2015059303A1 (enExample)
ZA (1) ZA201603646B (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015030881A2 (pt) 2013-06-14 2017-10-24 Psioxus Theraupeutics Ltd “regime de dosagem e formulações para adenovírus de tipo b”
LT3021859T (lt) 2013-10-25 2018-06-11 Psioxus Therapeutics Limited Onkolitiniai adenovirusai su heterologiniais genais
GB201406608D0 (en) * 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
GB201510197D0 (en) 2014-06-12 2015-07-29 Psioxus Therapeutics Ltd Method of treating ovarian cancer
JP2017529070A (ja) 2014-08-27 2017-10-05 サイオクサス セラピューティクス リミテッド アデノウイルスの製造方法
WO2016134371A2 (en) 2015-02-20 2016-08-25 Ohio State Innovation Foundation Bivalent antibody directed against nkg2d and tumor associated antigens
HK1250918A1 (zh) 2015-04-06 2019-01-18 Cytoimmune Therapeutics, Inc. 用於胶质母细胞瘤的egfr导向的car疗法
HRP20200439T1 (hr) * 2015-04-30 2020-06-12 Psioxus Therapeutics Limited Onkolitički adenovirus koji kodira protein b7
MY193281A (en) * 2015-12-17 2022-09-30 Psioxus Therapeutics Ltd Group b adenovirus encoding an anti-tcr-complex antibody or fragment
CN109312309B (zh) 2016-01-08 2024-04-02 雷普利穆内有限公司 工程化的病毒
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
GB201713765D0 (en) * 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
KR102427563B1 (ko) * 2016-08-29 2022-08-03 싸이오서스 테라퓨틱스 엘티디. 이중특이성 T 세포 활성화제(Bispecific T cell activator)가 보강된 아데노바이러스
WO2018083258A1 (en) * 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding at least three transgenes
WO2018083257A1 (en) * 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
WO2018083259A1 (en) * 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
GB201700350D0 (en) * 2017-01-09 2017-02-22 Replimune Ltd Altered virus
WO2018170763A1 (zh) * 2017-03-22 2018-09-27 深圳市博奥康生物科技有限公司 ILA 基因的 RNAi 表达载体及其构建方法和应用
TWI796329B (zh) 2017-04-07 2023-03-21 美商默沙東有限責任公司 抗－ilt4抗體及抗原結合片段
CN118308311A (zh) * 2017-06-01 2024-07-09 阿卡米斯生物公司 溶瘤病毒和方法
WO2019077113A1 (en) 2017-10-20 2019-04-25 F. Hoffmann-La Roche Ag COPY PROTECTION FOR ANTIBODIES
GB201801614D0 (en) 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation
WO2020010284A1 (en) * 2018-07-04 2020-01-09 Cytoimmune Therapeutics, LLC Compositions and methods for immunotherapy targeting flt3, pd-1, and/or pd-l1
NZ771198A (en) 2018-07-11 2024-11-29 Actym Therapeutics Inc Engineered immunostimulatory bacterial strains and uses thereof
JP2022502074A (ja) * 2018-09-10 2022-01-11 ジェネセイル バイオテック（シャンハイ）カンパニー リミテッド 改変された腫瘍溶解性ウイルス、組成物、およびその使用
JP2022521268A (ja) * 2019-02-21 2022-04-06 アンリーシュ イミュノ オンカリティクス，インコーポレイテッド 腫瘍溶解性アデノウイルスベクター及び使用法
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
MX2021010273A (es) 2019-02-27 2021-09-23 Actym Therapeutics Inc Bacterias inmunoestimuladoras modificadas para colonizar tumores, celulas inmunitarias residentes de tumor y el microentorno tumoral.
GB201909081D0 (en) 2019-06-25 2019-08-07 Psioxus Therapeutics Ltd Method
CA3161450A1 (en) 2019-11-12 2021-05-20 Actym Therapeutics, Inc. Immunostimulatory bacteria delivery platforms and their use for delivery of therapeutic products
KR20210118757A (ko) * 2020-03-23 2021-10-01 (주)큐리진 STAT3 및 mTOR를 이중 특이적으로 표적하는 핵산서열을 포함한 항암 바이러스
WO2021194181A1 (ko) * 2020-03-23 2021-09-30 ㈜큐리진 Ar 및 mtor를 이중 특이적으로 표적하는 핵산분자를 포함하는 항암바이러스
EP4148126A4 (en) * 2020-03-25 2025-01-08 Curigin Co.,Ltd. ANTI-TUMOR ADENOVIRUS IMMUNO-EVASIVE
JP2023520402A (ja) * 2020-03-31 2023-05-17 ウルトラジェニックス ファーマシューティカル インコーポレイテッド プロピオン酸血症を処置するための遺伝子治療
JP2023539454A (ja) 2020-08-12 2023-09-14 アクティム・セラピューティクス・インコーポレイテッド 免疫刺激細菌ベースのワクチン、治療薬およびｒｎａデリバリープラットフォーム
CN114717203B (zh) * 2020-12-22 2023-06-27 广东东阳光药业有限公司 一种hIL7/hCCL19双基因重组溶瘤病毒及其制备方法和用途
US20240108752A1 (en) * 2020-12-22 2024-04-04 Ensoma, Inc. Adenoviral gene therapy vectors
GB202102049D0 (en) 2021-02-13 2021-03-31 Psioxus Therapeutics Ltd Viruses
US20240398939A1 (en) 2021-09-23 2024-12-05 Sagittarius Bio, Inc. Adenoviruses and methods for using adenoviruses
EP4429682A2 (en) 2021-11-09 2024-09-18 Actym Therapeutics, Inc. Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment
US20250161447A1 (en) * 2022-03-03 2025-05-22 Board Of Regents, The University Of Texas System Anti-cd19 and anti-cd79b chimeric antigen receptors and methods of use thereof
CN116836283B (zh) * 2022-05-17 2024-05-07 苏州万灏生物科技有限公司 具有多种免疫调节因子的增强型溶瘤病毒及其制备方法和应用
WO2024243578A1 (en) 2023-05-25 2024-11-28 Dispatch Biotherapeutics, Inc. Synthetic cancer antigens as targets for treating cancers
WO2025171388A1 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens with modified domains and related methods and uses
WO2025171383A2 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens and related methods and uses

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005118825A2 (en) * 2004-05-26 2005-12-15 Schering Aktiengesellschaft Chimeric adenoviruses for use in cancer treatment
WO2006060314A2 (en) * 2004-12-01 2006-06-08 Bayer Schering Pharma Aktiengesellschaft Generation of replication competent viruses for therapeutic use

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0170269A3 (en) 1984-08-02 1987-09-23 Kao Corporation Medicated cosmetic compositions
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0542810A1 (en) 1990-08-02 1993-05-26 B.R. Centre Limited Methods for the production of proteins with a desired function
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
US5358866A (en) 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
FI951138L (fi) 1993-07-13 1995-04-13 Rhone Poulenc Rorer Sa Puuttellisia adenovirusvektoreita ja niiden käyttö geeniterapiassa
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5830686A (en) 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
US5677170A (en) 1994-03-02 1997-10-14 The Johns Hopkins University In vitro transposition of artificial transposons
FR2730504B1 (fr) * 1995-02-13 1997-03-28 Rhone Poulenc Rorer Sa Procede de preparation de genomes d'adenovirus recombinants
DE19648650C2 (de) 1996-01-29 1998-07-02 Schering Ag Puffersysteme und deren Verwendung zur Stabilisierung pharmazeutischer Zubereitung
US5877011A (en) 1996-11-20 1999-03-02 Genzyme Corporation Chimeric adenoviral vectors
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
CN1242051A (zh) 1996-12-31 2000-01-19 昂尼克斯药物公司 用于肿瘤治疗和预防的致细胞病变病毒
US6420524B1 (en) 1997-02-20 2002-07-16 Johns Hopkins University School Of Medicine Gain of function mutations in ATP-dependent transposition proteins
IL135507A0 (en) 1997-10-09 2001-05-20 Pro Virus Inc Treatment of neoplasms with viruses
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US6291214B1 (en) 1998-05-11 2001-09-18 Glaxo Wellcome Inc. System for generating recombinant viruses
US20020019051A1 (en) 1998-05-27 2002-02-14 Monika Lusky Chimeric adenoviral vectors
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
CN1110553C (zh) 1998-07-15 2003-06-04 杭州赛狮生物技术开发有限公司 基因工程腺病毒及其用途
CN1257286C (zh) * 1998-08-27 2006-05-24 森泰莱昂公司 用于递送异源基因的定向腺病毒载体
AU767975B2 (en) 1998-09-11 2003-11-27 Genvec, Inc. Alternatively targeted adenovirus
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
CA2678259C (en) 1998-12-09 2016-10-18 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services A recombinant vector expressing multiple costimulatory molecules and uses thereof
ATE332364T1 (de) 1999-02-22 2006-07-15 Transgene Sa Verfahren zur gewinnung von purifizierter virenzuammensetzung
CA2364562A1 (fr) 1999-04-09 2000-10-19 Aventis Pharma S.A. Composition destinee a la conservation d'adenovirus recombinants infectieux
DK1681353T3 (da) 1999-05-17 2010-01-04 Crucell Holland Bv Af adenovirus afledte genoverförselsvehikler indeholdende mindste ét element af adenovirus type 35
WO2000073478A2 (en) 1999-06-01 2000-12-07 University Of Washington Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration
WO2001011034A2 (en) 1999-08-09 2001-02-15 Targeted Genetics Corporation Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms intrastrand base pairs
US7396679B2 (en) 1999-11-15 2008-07-08 Onyx Pharmaceuticals, Inc. Oncolytic adenovirus
US7223593B2 (en) 2000-01-21 2007-05-29 Biovex Limited Herpes virus strains for gene therapy
US7456009B2 (en) 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
JP2003534806A (ja) 2000-05-31 2003-11-25 ジェンベク、インコーポレイティッド アデノウイルスベクターのターゲティングの方法および組成物
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
WO2001094413A2 (en) 2000-06-06 2001-12-13 Bristol-Myers Squibb Company B7-related nucleic acids and polypeptides and their uses for immunomodulation
ATE449859T1 (de) 2001-01-04 2009-12-15 Goeran Wadell Virusvektor zur gentherapie
US20050175589A1 (en) 2001-07-13 2005-08-11 Btg International Limited Anti-neoplastic viral agents
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
EP1327688A1 (en) 2002-01-14 2003-07-16 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Adenoviruses with enhanced lytic potency
CA2474777A1 (en) 2002-02-01 2003-08-07 Transgene S.A. Adenoviral vectors for modulating the cellular activities associated with pods
US20060147420A1 (en) * 2004-03-10 2006-07-06 Juan Fueyo Oncolytic adenovirus armed with therapeutic genes
WO2003092594A2 (en) 2002-04-30 2003-11-13 Duke University Adeno-associated viral vectors and methods for their production from hybrid adenovirus and for their use
JP4603894B2 (ja) 2002-12-03 2010-12-22 ユセベ ファルマ ソシエテ アノニム 抗体産生細胞を同定するためのアッセイ
US20040167088A1 (en) 2003-02-25 2004-08-26 Genvec, Inc. Method of using adenoviral vectors with increased persistence in vivo
US20040213764A1 (en) 2003-03-28 2004-10-28 William Wold Adenovirus replication-competent vectors expressing trail
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
DK1644412T4 (en) 2003-07-01 2018-11-12 Ucb Biopharma Sprl MODIFIED ANTIBODY-FAB FRAGMENTS
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
CN1934253A (zh) 2003-07-18 2007-03-21 昂尼克斯药物公司 用于治疗疾病的b亚组腺病毒载体
US20050186178A1 (en) 2003-08-28 2005-08-25 Ennist David L. Oncolytic adenoviral vectors encoding GM-CSF
US8076459B2 (en) 2003-10-16 2011-12-13 Micromet Ag Multispecfic deimmunized CD3-binders
WO2005107474A2 (en) * 2004-04-30 2005-11-17 Introgen Therapeutics, Inc. Oncolytic adenovirus armed with therapeutic genes
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
CN100361710C (zh) 2004-06-07 2008-01-16 成都康弘生物科技有限公司 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用
US20060292682A1 (en) 2004-07-22 2006-12-28 Hawkins Lynda K Addition of transgenes into adenoviral vectors
CA2589602A1 (en) 2004-09-01 2006-04-13 Genvec, Inc. Adenoviral vectors able to transduce apcs, potential use in immune response generation
US20060205080A1 (en) 2005-03-01 2006-09-14 David Frey Formulations for therapeutic viruses having enhanced storage stability
CA2620495A1 (en) 2005-08-31 2007-03-08 Genvec, Inc. Adenoviral vector-based malaria vaccines
CN1961961B (zh) 2005-11-11 2010-05-26 深圳市源兴生物医药科技有限公司 一种药物制剂及其制备方法
DE102005055128B4 (de) 2005-11-15 2015-04-02 Universität Rostock Viraler Vektor, dessen Verwendung zur Therapie von Leberzellkarzinomen und pharmazeutische Mittel umfassend den Vektor
ES2304281B1 (es) 2006-02-01 2009-08-12 Dnatrix Inc. Adenovirus oncoliticos para el tratamiento del cancer.
US8216819B2 (en) 2006-12-22 2012-07-10 Psioxus Therapeutics Limited Generation of oncolytic adenoviruses and uses thereof
CA2700714C (en) 2007-09-26 2018-09-11 Ucb Pharma S.A. Dual specificity antibody fusions
US20110034560A1 (en) 2008-01-29 2011-02-10 Sven Jacobson Liquid formulations of compounds active at sulfonylurea receptors
CA2723580A1 (en) 2008-05-27 2009-12-03 Oncolytics Biotech Inc. Modulating interstitial pressure and oncolytic viral delivery and distribution
CA2737241C (en) 2008-09-26 2017-08-29 Ucb Pharma S.A. Multivalent antibody fusion proteins
AU2009299791B2 (en) 2008-10-01 2016-02-25 Amgen Research (Munich) Gmbh Cross-species-specific PSCAxCD3, CD19xCD3, C-METxCD3, EndosialinxCD3, EpCAMxC D3, IGF-1RxCD3 or FAPalpha xCD3 bispecific single chain antibody
ES2385251B1 (es) * 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
US20100297072A1 (en) 2009-05-19 2010-11-25 Depinho Ronald A Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy
WO2011043719A1 (en) 2009-10-05 2011-04-14 Ya-Fang Mei Replicating viral vectors for gene therapy
KR101957616B1 (ko) 2010-08-16 2019-03-12 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 아데노바이러스 조립 방법
WO2012038606A1 (en) 2010-09-24 2012-03-29 Oncos Therapeutics Oy Oncolytic adenoviral vectors coding for monoclonal anti - ctla - 4 antibodies
PE20141521A1 (es) 2011-08-23 2014-10-25 Roche Glycart Ag Moleculas biespecificas de union a antigeno activadoras de celulas t
WO2013074507A2 (en) 2011-11-14 2013-05-23 Regenerative Sciences, Llc Suspended particle delivery systems and methods
CN102586327B (zh) 2012-01-18 2013-09-11 陕西师范大学 一步法构建携带外源基因的d24纤维蛋白修饰的条件复制型腺病毒载体及其应用
NZ701324A (en) 2012-05-04 2016-09-30 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
US9314519B2 (en) 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
WO2014138314A1 (en) 2013-03-05 2014-09-12 Baylor College Of Medicine Oncolytic virus
WO2015040234A1 (en) 2013-09-23 2015-03-26 Crucell Holland B.V. Adenovirus formulations
GB201322851D0 (en) 2013-12-23 2014-02-12 Psioxus Therapeutics Ltd Method
GB201318793D0 (en) 2013-10-24 2013-12-11 Plaquetec Ltd Vascular Biomarkers
LT3021859T (lt) 2013-10-25 2018-06-11 Psioxus Therapeutics Limited Onkolitiniai adenovirusai su heterologiniais genais
CN106029889A (zh) 2013-11-22 2016-10-12 德那翠丝有限公司 表达免疫细胞刺激受体激动剂的腺病毒
CN112759650B (zh) 2014-04-03 2024-10-01 Igm生物科学股份有限公司 修饰的j链
GB201406608D0 (en) 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
JP2017529070A (ja) 2014-08-27 2017-10-05 サイオクサス セラピューティクス リミテッド アデノウイルスの製造方法
GB201503500D0 (en) 2015-03-02 2015-04-15 Ucl Business Plc Cell
KR102626276B1 (ko) 2015-03-17 2024-01-17 틸트 바이오세러퓨틱스 오이 이-특이적인 항체를 암호화하는 종양붕괴성 아데노바이러스 및 이와 관련된 방법 및 용도
HRP20200439T1 (hr) 2015-04-30 2020-06-12 Psioxus Therapeutics Limited Onkolitički adenovirus koji kodira protein b7
MY193281A (en) 2015-12-17 2022-09-30 Psioxus Therapeutics Ltd Group b adenovirus encoding an anti-tcr-complex antibody or fragment
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
KR102427563B1 (ko) 2016-08-29 2022-08-03 싸이오서스 테라퓨틱스 엘티디. 이중특이성 T 세포 활성화제(Bispecific T cell activator)가 보강된 아데노바이러스
AU2017345764A1 (en) 2016-10-20 2019-05-02 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
WO2018083259A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
WO2018083257A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
WO2018083258A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding at least three transgenes
GB201801614D0 (en) 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005118825A2 (en) * 2004-05-26 2005-12-15 Schering Aktiengesellschaft Chimeric adenoviruses for use in cancer treatment
WO2006060314A2 (en) * 2004-12-01 2006-06-08 Bayer Schering Pharma Aktiengesellschaft Generation of replication competent viruses for therapeutic use

Also Published As

Publication number Publication date
PH12016500759A1 (en) 2016-05-30
BR112016008973A2 (pt) 2017-09-19
ZA201603646B (en) 2017-09-27
IL269304A (en) 2019-11-28
KR20160067184A (ko) 2016-06-13
LT3021859T (lt) 2018-06-11
NO3021859T3 (enExample) 2018-04-28
EA036414B1 (ru) 2020-11-09
AU2014338864B2 (en) 2019-11-21
WO2015059303A1 (en) 2015-04-30
SG10201804030WA (en) 2018-07-30
MX2016005170A (es) 2017-02-02
US20180311291A1 (en) 2018-11-01
CN108064159A (zh) 2018-05-22
SA516371011B1 (ar) 2020-08-13
DK3021859T3 (en) 2018-03-05
KR102272932B1 (ko) 2021-07-05
EP3831398A1 (en) 2021-06-09
EP3021859B1 (en) 2017-11-29
PE20160951A1 (es) 2016-09-17
US20210187047A1 (en) 2021-06-24
EA201690545A1 (ru) 2016-09-30
IL244944B (en) 2019-09-26
RS57043B1 (sr) 2018-05-31
PT3021859T (pt) 2018-03-09
PH12016500759B1 (en) 2016-05-30
EP3021859A1 (en) 2016-05-25
AU2014338864A8 (en) 2018-08-23
US9987314B2 (en) 2018-06-05
MY175614A (en) 2020-07-01
CL2016000959A1 (es) 2016-12-02
CN108064159B (zh) 2021-12-10
SI3021859T1 (en) 2018-04-30
US20240325472A1 (en) 2024-10-03
AU2014338864A1 (en) 2016-05-05
US20160331793A1 (en) 2016-11-17
EP3372236A1 (en) 2018-09-12
HUE035875T2 (hu) 2018-06-28
HRP20180317T1 (hr) 2018-07-13
NZ718931A (en) 2022-10-28
SMT201800130T1 (it) 2018-05-02
CA3183645A1 (en) 2015-04-30
US11439678B2 (en) 2022-09-13
CY1119955T1 (el) 2018-12-12
IL269304B (en) 2020-06-30
IL244944A0 (en) 2016-05-31
ES2661132T3 (es) 2018-03-27
SG11201602887QA (en) 2016-05-30
PL3021859T3 (pl) 2018-06-29
TR201802728T4 (tr) 2018-03-21
CN114457044A (zh) 2022-05-10
CA2927968A1 (en) 2015-04-30
US11938159B2 (en) 2024-03-26
MX373835B (es) 2020-07-08
CA2927968C (en) 2023-02-21

Similar Documents

Publication Publication Date Title
AU2014338864C1 (en) Oncolytic adenoviruses armed with heterologous genes
AU2017320776B2 (en) Adenovirus armed with bispecific T cell activator
AU2019315440B2 (en) Improving the efficacy and safety of adoptive cellular therapies
RU2747011C2 (ru) Общие легкие цепи и способы их применения
KR102794512B1 (ko) 그룹 b 아데노바이러스-함유 제형
KR20170044194A (ko) 아데노바이러스의 제조를 위한 공정
KR102863518B1 (ko) 세이프 하버 좌위 내로의 항체 코딩 서열의 삽입을 위한 방법 및 조성물
CN111954680B (zh) IL2Rβ/共同γ链抗体
AU2018322776B2 (en) Adenovirus armed with bispecific T cell engager (BiTE)
CN1961002A (zh) 能中和狂犬病病毒的结合分子及其应用
KR20190141655A (ko) 종양 형질도입용 조성물 및 방법
CN113227144A (zh) 用于生成car-t细胞的两类基因载体及其用途
KR20210113655A (ko) 전립선 신생항원 및 이의 용도
SG175682A1 (en) Selection of human monoclonal antibodies by mammalian cell display
TW202216777A (zh) 四面體抗體
KR20220150320A (ko) Hiv 치료를 위한 림프구에서 외생성 인자의 주문형 발현
TW202233841A (zh) 用於眼適應症之載體化抗ＴＮＦ－α抗體
KR102370150B1 (ko) 전사 조절 인자 및 이의 외래 단백질 발현 증강에 있어서의 응용
CN115176016B (zh) 增强的表达系统及其使用方法
CN114480413B (zh) 一种活化肿瘤免疫应答的基因修饰干细胞制备方法
TW202241943A (zh) Tau特異性抗體基因療法組合物、方法及其用途
HK40060008A (en) Two-gene vectors for generating car-t cells and uses thereof
EA044725B1 (ru) Композиции и способы получения антител, основанные на применении локусов, обеспечивающих повышенную экспрессию

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 30 , NO 18 , PAGE(S) 2499 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME PSIOXUS THERAPEUTICS LIMITED, APPLICATION NO. 2014338864, UNDER INID (72) CORRECT THE CO-INVENTOR TO NICOLSON, TAMARA

FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 19 MAR 2020

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 19 MAR 2020

HB Alteration of name in register

Owner name: AKAMIS BIO LIMITED

Free format text: FORMER NAME(S): PSIOXUS THERAPEUTICS LIMITED